Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants

A Phase 1, Randomized, Placebo-controlled, Descending Age, Dose-escalation Study to Assess the Safety and Immunogenicity of an Investigational Non-Replicating Rotavirus Vaccine (MT-5625) in Healthy Adults, Toddlers and Infants

A study to investigate the safety and reactogenicity of MT-5625 independently in adults aged 18-35 years, toddlers ages 12-24 months, and infants aged 6-10 weeks

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Biological: Placebo; Biological: MT-5625 middle dose; Biological: MT-5625 high dose; Biological: MT-5625 low dose; Biological: Rotarix

• Study Type: Interventional
• Enrollment (Actual): 110
• Phase: Phase 1

Contacts and Locations

Study Locations

• Australia
  • Adelaide, Australia
    • Investigational center
• South Africa
  • Johannesburg, South Africa
    • Investigational center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 month to 35 years (Child, Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Healthy male or female adults/toddlers/infants as established by medical history and clinical examination before entering the study
• Adults aged >18 and < 35, toddlers aged >12 and < 24 months, and infants aged > 6 and < 10 weeks at the time of enrollment
• Subject (or Parent/Legal Guardian) willing and able to give written informed consent after the nature of the study has been explained
• Subject (or Parent/Legal Guardian) willing to comply with the study restrictions and study schedule and to remain in the area for the study duration
• Females of potential childbearing must not be pregnant or breastfeeding and willing to use adequate method of contraception during the trial

Exclusion Criteria:

ALL SUBJECTS

• Presence of fever or other acute illness
• Concurrent participation in another clinical trial or receipt of an investigational product during the 30 days prior to randomization
• Suspected or known impairment of immune function
• Known sensitivity to any components of the study vaccine
• History of anaphylactic reaction
• Receipt of immunoglobulin therapy or blood products in last 6 months
• History of chronic immunosuppressive medications (with the exception of inhaled or topical steroids)
• History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study

ADULTS ONLY

• Have received any vaccine within 4 weeks prior to randomization
• Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of investigational product (IP)
• Any clinically significant abnormalities on 12-lead ECG as judged by the Investigator
• Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV) antibody
• Have any contraindications to parenteral injections ( eg history of bleeding disorder)
• Known or suspected history of alcohol or drug abuse or excessive intake of alcohol as judged by the Investigator
• Donated blood within the 4 weeks prior to randomization

TODDLERS and INFANTS

• Received any vaccine within 14 days of randomization
• Presence of malnutrition or other systemic disorders
• History of congenital abdominal disorders, intussusception or abdominal surgery
• Major congenital or genetic defect

TODDLERS ONLY

• Any positive result on screening for serum hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody, and human immunodeficiency virus (HIV) antibody.

INFANTS ONLY

• Infants with history of premature birth (<37 weeks gestational age)
• Infants who have received rotavirus vaccine in the past
• Known sensitivity to any components of the study vaccine, including Rotarix®
• Any positive result on screening for serum hepatitis B surface antigen, hepatitis B core antibody, and hepatitis C antibody
• HIV infection assessed by PCR if mother is not known to be negative (negative test result between 24 weeks gestation and screening).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

8

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Adult MT-5625 middle dose; Adult receiving intramuscular injection with either middle dose of MT-5625 or placebo	Biological: Placebo; Intramuscular injection; Biological: MT-5625 middle dose; Intramuscular injection
Experimental: Adult MT-5625 high dose; Adult receiving intramuscular injection with either high dose of MT-5625 or placebo	Biological: Placebo; Intramuscular injection; Biological: MT-5625 high dose; Intramuscular injection
Experimental: Toddler MT-5625 middle dose; Toddler receiving intramuscular injection with either middle dose of MT-5625 or placebo	Biological: Placebo; Intramuscular injection; Biological: MT-5625 middle dose; Intramuscular injection
Experimental: Toddler MT-5625 high dose; Toddler receiving intramuscular injection with either high dose of MT-5625 or placebo	Biological: Placebo; Intramuscular injection; Biological: MT-5625 high dose; Intramuscular injection
Experimental: Infant MT-5625 low dose; Infant receiving intramuscular injection with either low dose of MT-5625 or placebo	Biological: Placebo; Intramuscular injection; Biological: MT-5625 low dose; Intramuscular injection
Experimental: Infant MT-5625 middle dose; Infant receiving intramuscular injection with either middle dose of MT-5625 or placebo	Biological: Placebo; Intramuscular injection; Biological: MT-5625 middle dose; Intramuscular injection
Experimental: Infant MT-5625 high dose; Infant receiving intramuscular injection with either high dose of MT-5625 or placebo	Biological: Placebo; Intramuscular injection; Biological: MT-5625 high dose; Intramuscular injection
Active Comparator: Rotarix; Infant receiving oral administration with Rotarix	Biological: Rotarix; Oral administration

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Proportion of subjects with local reactions and reactogenicity events.	Within 7 days after each vaccination
Proportion of subjects reporting adverse events.	Within 28 days after each vaccination

Secondary Outcome Measures

Outcome Measure	Time Frame
Proportion of subjects with anti-MT-5625 IgG seroresponses	Day 28 after each vaccination
Proportion of subjects with neutralizing antibody responses	Day 28 after each vaccination
Anti-MT-5625 IgG geometric mean titers (GMTs) 28 days after each injection in adults, toddlers, and infants.	Day 28 after each vaccination
Neutralizing antibody GMTs against rotavirus 28 days after each injection in adults, toddlers and infants.	Day 28 after each vaccination

Collaborators and Investigators

• Sponsor: Mitsubishi Tanabe Pharma Corporation

Publications and helpful links

General Publications

• Kurokawa N, Robinson MK, Bernard C, Kawaguchi Y, Koujin Y, Koen A, Madhi S, Polasek TM, McNeal M, Dargis M, Couture MM, Trepanier S, Forrest BD, Tsutsui N. Safety and immunogenicity of a plant-derived rotavirus-like particle vaccine in adults, toddlers and infants. Vaccine. 2021 Sep 15;39(39):5513-5523. doi: 10.1016/j.vaccine.2021.08.052. Epub 2021 Aug 25.

Study record dates

Study Major Dates

• Study Start (Actual): July 3, 2018
• Primary Completion (Actual): June 28, 2019
• Study Completion (Actual): June 28, 2019

Study Registration Dates

• First Submitted: April 15, 2018
• First Submitted That Met QC Criteria: April 15, 2018
• First Posted (Actual): April 25, 2018

Study Record Updates

• Last Update Posted (Actual): August 6, 2019
• Last Update Submitted That Met QC Criteria: August 4, 2019
• Last Verified: August 1, 2019

More Information

Terms related to this study

• Other Study ID Numbers: MT-5625-01

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No